Cariprazine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Cariprazine

Examples of brand names: Reagila [EU/DE]

ATC code: N05AX15

Main use (for orientation): Schizophrenia

Documented research summary

A retrospective case report from an adverse-event collection describes abdominal pain and liver injury with cariprazine plus THC-dominant cannabis, with concomitant etoricoxib/chondroitin. CYP3A4 inhibition is hypothetical; concentrations are absent. Positive treatment courses in cannabis use disorder do not refute the signal.

Uncertainties and limitations

Does not establish safety for less-studied cannabinoids or untested formulations/doses.

Do not infer clinical dosage from preclinical effects or enzyme hypotheses.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THC/CBD-containing cannabis (THC 20%, CBD 1%; not an isolate study) – clinical signals

Finding ID: B0332

Type of result: Clinical case signal; causal attribution uncertain

Observation: Abdominal pain and hepatotoxicity (ALT 850 U/L, GGT 480 U/L) in a 65-year-old woman.

Mechanism: Suspected CYP3A4 inhibition; not confirmed by concentration measurements.

Study type: Retrospective evaluation of adverse-event reports; one cariprazine case

Context studied: Cannabis for osteoarthritis pain; cariprazine dose not stated; concomitant etoricoxib and chondroitin sulphate. Overall collection of 20 selected suspected interaction cases, not exposure-based incidence.

Clinical interpretation: Specific clinical warning signal, not a quantified risk or direct proof of a pharmacokinetic mechanism.

Limitations and uncertainties: Multiple medicines and selected reports; no measured drug/cannabinoid concentrations, no isolated THC/CBD attribution. Authors' hypotheses not adopted as proven mechanisms.

Original sources for this finding: Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs. [CA_P_39502532]

References and access status

[C_LABEL_D0125] VRAYLAR (CARIPRAZINE) CAPSULE, GELATIN COATED VRAYLAR (CARIPRAZINE) KIT [ALLERGAN, INC.]

Original source / bibliographic reference

Authors: ALLERGAN, INC.

Year: 2025

Source type: US Structured Product Label

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_39502532] Green rush and red warnings: Retrospective chart review of adverse events of interactions between cannabinoids and psychotropic drugs.

Original source / bibliographic reference

Authors: Chrobak AA, Woroń J, Siwek M.

Year: 2024

Source type: research-article; Journal Article

DOI: 10.3389/fphar.2024.1500312

PMID: 39502532

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[C_PR_39319529] Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder.

Original source / bibliographic reference

Authors: Szerman N, Vega P, Roncero C, Peris L, Grau-López L, Basurte-Villamor I.

Year: 2025

Source type: Primary source, full text read

DOI: 10.1097/yic.0000000000000568

PMID: 39319529

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

[C_PR_42651098] Cariprazine in First-Episode Psychosis with Comorbid Cannabis Use: A Case Series of Eight Patients from Two Greek Early Intervention Units.

Original source / bibliographic reference

Authors: Ntouros E, Partsanaki DC, Dimitrakopoulos S, Nazlidou EI, Spatharas VI, Mavreas V, Bozikas VP.

Year: 2026

Source type: Primary source, full text read

DOI: 10.3390/brainsci16080787

PMID: 42651098

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility